Clinical Trial Update: Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on almonertinib for advanced non-small cell lung cancer with rare EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Safety of Almonertinib | Phase 2 | Status: UNKNOWN